BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 26213358)

  • 1. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
    Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
    Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
    JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction.
    Reeh M; Mina S; Bockhorn M; Kutup A; Nentwich MF; Marx A; Sauter G; Rösch T; Izbicki JR; Bogoevski D
    Br J Surg; 2012 Oct; 99(10):1406-14. PubMed ID: 22961520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
    Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoresponse after non-curative gastrectomy for M1 gastric cancer.
    Shin HB; Lee SH; Son YG; Ryu SW; Sohn SS
    World J Surg Oncol; 2015 Jan; 13():13. PubMed ID: 25634223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term survival after eso-gastrectomy for esophagogastric junction adenocarcinoma--prospective study].
    Bîrlă R; Iosif C; Mocanu A; Gîndea C; Hoară P; Panaitescu E; Constantinoiu S
    Chirurgia (Bucur); 2008; 103(6):635-42. PubMed ID: 19274907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
    Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized surgical strategies for cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
    Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
    Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
    Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
    Peracchia A; Bonavina L; Via A; Incarbone R
    J Exp Clin Cancer Res; 1999 Sep; 18(3):289-94. PubMed ID: 10606171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.